Financial reports
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
5 May 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
17 Mar 22
Current reports
8-K
Regulation FD Disclosure
30 Jan 24
8-K
AVROBIO and Tectonic Therapeutic Announce Merger
30 Jan 24
8-K
AVROBIO to Explore Strategic Alternatives
12 Jul 23
8-K/A
Cost Associated with Exit or Disposal Activities
14 Jun 23
8-K
Other Events
13 Jun 23
8-K
Termination of a Material Definitive Agreement
12 Jun 23
8-K
Departure of Directors or Certain Officers
9 Jun 23
8-K
AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million
22 May 23
8-K
AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of
18 May 23
8-K
AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
Registration and prospectus
425
Business combination disclosure
4 Apr 24
S-4
Registration of securities issued in business combination transactions
13 Feb 24
425
Business combination disclosure
30 Jan 24
425
Business combination disclosure
30 Jan 24
425
Business combination disclosure
30 Jan 24
RW
Registration withdrawal request
3 Nov 23
S-8
Registration of securities for employees
23 Mar 23
S-3
Shelf registration
8 Nov 22
Proxies
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 19
Other
EFFECT
Notice of effectiveness
15 Jan 20
CORRESP
Correspondence with SEC
10 Jan 20
CORRESP
Correspondence with SEC
2 Jan 20
UPLOAD
Letter from SEC
27 Dec 19
EFFECT
Notice of effectiveness
11 Jul 19
CORRESP
Correspondence with SEC
8 Jul 19
UPLOAD
Letter from SEC
3 Jul 19
CT ORDER
Confidential treatment order
21 Jun 18
EFFECT
Notice of effectiveness
21 Jun 18
CERT
Certification of approval for exchange listing
19 Jun 18
Ownership
SC 13G
Newtyn Management, LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
GMT CAPITAL CORP
13 Feb 24
SC 13G/A
BML Investment Partners, L.P.
7 Feb 24
4
Azadeh Golipour
5 Feb 24
4
Essra Ridha
5 Feb 24
4
Erik Ostrowski
5 Feb 24
4
Steven Avruch
5 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
24 Jan 24
SC 13G
BML Investment Partners, L.P.
24 Jul 23